Vizora日本語

Japan Tissue EngineeringJapan Tissue Engineering Co., Ltd.7774東証グロース精密機器FY ending Mar 2026, non-consolidated, J-GAAP

Japan Tissue Engineering FY ending Mar 2020 results

About 59% of Japan Tissue Engineering's sales come from Regenerative Medicine Business, with Custom Development and Manufacturing Business and Research and Development Support Business making up much of the rest.

It lost about ¥10 for every ¥100 of sales at the operating level.

Where the money goes

Where ¥100 of sales goes

For every ¥100 Japan Tissue Engineering sells, how much goes where, and how much is kept.

FY ending Mar 2020
Cost of sales
¥48
SG&A
¥62
Operating loss
¥10
Net loss
¥12

Margin funnel (derived from reported values)Gross margin 51.4% → Operating margin -10.2% → Net margin -12.4%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第26期(2023/04/01－2024/03/31)

    ID S100TNDE2024-06-19Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第24期(2021/04/01－2022/03/31)

    ID S100Q2J82023-02-03Open

  • EDINET (FSA Japan)

    有価証券報告書－第23期(令和2年4月1日－令和3年3月31日)

    ID S100LOU72021-06-25Open

Extracted from XBRL: 33 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image